DDW 2015: Sofosbuvir/ Ledipasvir Cures Most Hepatitis C Patients with Cirrhosis

Sofosbuvir and ledipasvir -- the drugs in Harvoni -- are well-tolerated and highly effective for genotype 1 chronic hepatitis C patients with compensated cirrhosis, producing an overall cure rate of 96%, according to a pooled analysis of more than 500 participants in Phase 2 and 3 studies, according to a presentation at Digestive Disease Week 2015 this month in Washington, DC.

alt

Read more:

DDW 2015: Sofosbuvir + Daclatasvir for 12 Weeks Cures Most HIV/HCV Coinfected Patients

Nearly all HIV/HCV coinfected patients treated for 12 weeks with an interferon- and ribavirin-free regimen of sofosbuvir (Sovaldi) and daclatasvir (Daklinza) achieved sustained virological response, but the cure rate fell to 76% for those treated for only 8 weeks, according to results from the ALLY-2 trial presented at Digestive Disease Week 2015 this month in Washington, DC.

alt

Read more:

DDW 2015/EASL 2015: Statins Associated with Lower Risk of Death and Liver Decompensation

Hepatitis C patients with liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of U.S. veterans presented at the Digestive Disease Week meeting this week in Washington, DC, and at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another recent study found that statins were associated with better response to hepatitis C treatment and lower risk of liver cancer.

alt

Read more:

DDW 2015: Hepatitis C Treatment Could Yield Large Economic Benefit

Interferon-free direct-acting antiviral therapy that cures most people with chronic hepatitis C could lead to major economic benefits by reducing lost worker productivity, according to an analysis presented at Digestive Disease Week 2015, now underway in Washington, DC.

alt

Read more: